Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.36 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383806 | 1.00 | RXRA (0.40) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL24373739 | 0.85 | CYP4F2 (0.42) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL21196202 | 0.84 | RXRA (0.43) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL19616735 | 0.84 | RXRA (0.41) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL29385672 | 0.84 | RXRA (0.41) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL29478967 | 0.82 | RXRA (0.42) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL24373355 | 0.82 | CYP4F2 (0.42) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL29479102 | 0.82 | CYP4F2 (0.42) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL24373169 | 0.82 | RXRA (0.42) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL30959191 | 0.82 | ALDH1A1 (0.37) | RXRARXRBRXRGLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-114057744-A | Process for preparing imidazotriazine and pyrrolopyrimidine derivatives as inhibitors of KRAS G12C | 百济神州(北京)生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RXRA 2758/4885RXRB 2748/4885RXRG 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.